INS and metabolic dysfunction-associated steatohepatitis: The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD), including metabolic dysfunction-associated steatohepatitis (MASH), is predicted to surge from 83.1 million in 2015 to 190 million by 2030.1, 2, 3, 4, 5 MASLD can lead to cirrhosis or hepatocellular carcinoma due to factors, such as insulin resistance, microbiome composition, intestinal flora, and inflammatory cytokines.4